Correction to: Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions

被引：0
|
作者：
Aasha Harish
Stanley A. Schwartz
机构：
[1] University at Buffalo,Division of Allergy and Immunology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences
来源：
Clinical Reviews in Allergy & Immunology | 2020年 / 59卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original version of this article unfortunately contained a mistake in the fifth paragraph of the “Conclusion” section.
引用
收藏
页码：273 / 273
相关论文
共 50 条
  • [31] Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
    Bakakos, Agamemnon
    Rovina, Nikoleta
    Bakakos, Petros
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [32] Real World Corticosteroid Effect of Anti-IL-5/5Rα in Eosinophilic Asthma
    Christner, R.
    Quigley, D.
    Walsh, S.
    Harrison, M.
    Cusack, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [33] TOXOCARA-INDUCED EOSINOPHILIC INFLAMMATION - AIRWAY FUNCTION AND EFFECT OF ANTI-IL-5
    BUIJS, J
    EGBERS, MWEC
    LOKHORST, WH
    SAVELKOUL, HFJ
    NIJKAMP, FP
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (03) : 873 - 878
  • [34] REAL-WORLD EFFECTIVENESS OF ANTI-IL-5/5R THERAPIES IN SEVERE ATOPIC EOSINOPHILIC ASTHMATICS ELIGIBLE FOR ANTI-IGE THERAPY
    Jackson, D. J.
    Kavanagh, J.
    Roxas, C.
    D'Ancona, G.
    Green, L.
    Thomson, L.
    Fernandes, M.
    Dhariwal, J.
    Nanzer, A. M.
    Kent, B. D.
    THORAX, 2019, 74 : A137 - A138
  • [35] Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series
    Tashiro, Hiroki
    Takahashi, Koichiro
    Kurihara, Yuki
    Sadamatsu, Hironori
    Kuwahara, Yuki
    Kimura, Shinya
    Sueoka-Aragane, Naoko
    JOURNAL OF ASTHMA AND ALLERGY, 2022, 15 : 169 - 177
  • [36] Therapeutic approach with mepolizumab (anti-IL-5) in a series of patients with eosinophilic granulomatosis with polyangiitis
    Bizymi, N.
    Matthaiou, A. M.
    Stathakis, G.
    Viziriannaki, S.
    Bibaki, E.
    Tzanakis, N.
    Antoniou, K.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [37] Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
    Lombardi, Carlo
    Comberiati, Pasquale
    Ridolo, Erminia
    Cottini, Marcello
    Yacoub, Mona Rita
    Casagrande, Silvia
    Ricco, Matteo
    Bottazzoli, Marco
    Berti, Alvise
    DRUGS, 2024, 84 (06) : 661 - 684
  • [38] Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor α levels in patients with eosinophilic esophagitis
    Conus, Sebastien
    Straumann, Alex
    Simon, Hans-Uwe
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (01) : 269 - 269
  • [39] Occurrence of Sezary syndrome following the initiation of anti-IL-5 treatment
    Barre, Mathilde
    Amatore, Florent
    Avenin, Morgan
    Gorvel, Laurent
    Olive, Daniel
    Delaporte, Emmanuel
    EUROPEAN JOURNAL OF DERMATOLOGY, 2022, 32 (03) : 419 - 420
  • [40] A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis (Nov, 10.1007/s12325-022-02307-x, 2022)
    Koike, Haruki
    Nishi, Ryoji
    Yagi, Satoru
    Furukawa, Soma
    Fukami, Yuki
    Iijima, Masahiro
    Katsuno, Masahisa
    ADVANCES IN THERAPY, 2023, 40 (02) : 718 - 718
12345